Alterations in the expression of cytochrome c oxidase subunits in doxorubicin-resistant leukemia K562 cells

Biochemical Pharmacology
Fabienne GrandjeanMarie Hélène Ratinaud

Abstract

Doxorubicin (DOX), a widely used antitumoral drug, induces numerous modifications in sensitive cells, interacting with nuclear and mitochondrial DNA. In previous studies achieved in two K562 DOX-resistant sublines (K562/0.2R and K562/0.5R), we have shown stable mitochondrial damage comparatively with sensitive parental cells, such as decrease of cytochrome c oxidase activity (COX; EC 1.9.3.1) and cytochrome aa3 content. In order to explain these data, we have studied several COX genes and their expression, in relationship with altered COX activity and multidrug resistance (MDR) phenotype. We have observed a lower expression of the catalytic subunits COX I and II in MDR sublines, which was neither related to mutations in the corresponding mitochondrial genes, nor to a reduced transcription rate. In contrast, we have noticed an increase in both MDR K562 variants, in the mRNA expression of the catalytic subunit COX III, related to an increase in the half-life of these transcripts. Moreover, the doxorubicin resistance phenotype in K562 cells was accompanied by modifications of the expression and steady-state mRNA levels of several nuclear-encoded regulatory COX subunits. Thus, doxorubicin-resistant K562 cells represent an interesti...Continue Reading

References

Dec 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·F SangerA R Coulson
Jul 15, 1992·Biochemical and Biophysical Research Communications·T BourgeronP Rustin
Jan 1, 1990·Annual Review of Genetics·M C Costanzo, T D Fox
Jan 1, 1990·Annual Review of Biochemistry·R A Capaldi
Jan 1, 1990·Genetics·H Roman, M M Ruzinski
Jan 1, 1989·Annual Review of Biochemistry·J A Endicott, V Ling
Aug 1, 1987·Journal of Molecular and Cellular Cardiology·P K SingalL E Weinberg
Sep 3, 1984·Biochimica Et Biophysica Acta·E Goormaghtigh, J M Ruysschaert
Jan 15, 1982·Biochemical and Biophysical Research Communications·E GoormaghtighJ M Ruysschaert
Jul 5, 1982·Journal of Molecular Biology·J F DeatherageR A Capaldi
Apr 9, 1981·Nature·S AndersonI G Young
Nov 1, 1980·Biochemical Pharmacology·E GoormaghtighJ M Ruysschaert
Oct 15, 1993·Biochemical and Biophysical Research Communications·Z M Chrzanowska-LightowlersR N Lightowlers
Sep 15, 1993·Biochemical and Biophysical Research Communications·K AdachiH Toshima
Oct 1, 1996·Genome Research·C A HeidP M Williams
Apr 1, 1997·Journal of Bioenergetics and Biomembranes·J W Taanman
Oct 8, 1998·Biochemical Pharmacology·M Denis-GayM H Ratinaud
Feb 1, 1996·Trends in Cardiovascular Medicine·R C Scarpulla

❮ Previous
Next ❯

Citations

Feb 1, 2004·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Myung-Ju AhnYong-Sung Lee
Feb 17, 2009·Biophysical Journal·Karunakaran ChandranB Kalyanaraman
Feb 24, 2006·European Journal of Haematology·Fionnuala B Hickey, Thomas G Cotter
Jan 7, 2003·Molecular Cancer·Jennifer S Carew, Peng Huang
Nov 30, 2006·International Journal of Cancer. Journal International Du Cancer·Dirk LebrechtUlrich A Walker
Aug 25, 2004·The Journal of Pharmacy and Pharmacology·M SawickaW Lewandowski
Feb 17, 2007·The Journal of Biological Chemistry·Jian Li CampianJohn W Eaton

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.